Abstract
Introduction: HIV resistance to antiretroviral is currently a global concern, and requires increased surveillance in a context of widespread ARV treatment. Objective: To evaluate early warning indicators of HIV resistance to ARVs in the Hospital of Tivaouane (Senegal) where viral load was not routinely available. Methods: This is a cross-sectional retrospective study from 2008-2016. The etraction tool (May 2010 version) was used to analyze the EWI. Results: We collected 360 HIV positive patients followed on average for 3.57 years ± 3.02. 2009, 2010 and 2012 recorded 100% ARV prescribing rates. Throughout the study period, the percentage of patients lost to follow-up during the first 12 months of treatment was less than 20%. Virtually, all patients were still under primary ARVT over 12-month treatment. All patients (100%) withdrew their ARV drugs on time. No stock storage regarding various classes of ARVs was noted during the study period. Conclusion: At the end of this study we recommend to maintain regular follow-up of EWI, and combine it with the achievement of viral load.
Highlights
HIV resistance to antiretroviral is currently a global concern, and requires increased surveillance in a context of widespread ARV treatment
With the decentralization of access to ARVs performed in Senegal within regions in 2001, the number of Persons life of HIV (PLHIV) under ARV treatment increased significantly from 1855 patients in 2004 to 2151 in December 2017 and close to 62% of these patients under ARV lived in a decentralized area where virologic monitoring is not yet effective, due to some technical requirements that are generally to be considered in monitoring patients, plus problems connected to the collect and transfer of samples to agreed laboratories in the capital [2]
General Characteristics of PLHIV Followed in Tivaouane
Summary
HIV resistance to antiretroviral is currently a global concern, and requires increased surveillance in a context of widespread ARV treatment. Objective: To evaluate early warning indicators of HIV resistance to ARVs in the Hospital of Tivaouane (Senegal) where viral load was not routinely available. Throughout the study period, the percentage of patients lost to follow-up during the first 12 months of treatment was less than 20%. The WHO 2017 Report indicates in some places, a rate of resistance to some of the most used drugs against this virus, more than 10% [1]. The increased use of HIV treatment with ARVs in low- and middle-income countries is seen as a factor that has led to the resistance to some kinds of treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
